Intensifying oral diuretic therapy was linked to worse prognosis, but not everybody is sold on its use an endpoint.

Bayer announced the submission of a marketing authorization application to the Ministry of Health, Labour, and Welfare (MHLW) in Japan, seeking approval of finerenone in adult patients with chronic ...

Bayer's big investment in time and money on the development of finerenone for chronic kidney disease (CKD) in diabetics has paid off with an FDA approval, although it could face stiff competition ...

Bayer has claimed EU approval for Kerendia ... The approval is based on the phase 3 FIDELIO-DKD trial, in which Kerendia (finerenone) reduced the risk of kidney disease progression or renal ...

Bayer AG BAYRY reported fourth-quarter 2024 core earnings of 28 cents per American Depositary Receipt (ADR), in line with the ...

Bayer has also submitted regulatory approval applications in the United States and China for finerenone for the treatment of adult patients with heart failure with a left ventricular ejection ...

Bayer (BAYN: DE) has a prize asset on its hands with Kerendia (finerenone) and, more importantly, a solution for millions of patients. It recently became the first-and-only non-steroidal ...

Bayer is committed to exactly this. Through its core businesses in agriculture and healthcare, the company focuses on driving sustainable development and generating positive social impact.

Cash call worth about $9 billion based on current value Company says would only use the extra capital if essential Bayer has paid $10 billion on Roundup settlements Share price falls more than 6% ...